Mounjaro vs Ozempic: Two Brand Names, Two Molecules, and What the Trials Show

Ozempic and Mounjaro are brand names for two different molecules: Ozempic is semaglutide, a GLP-1 receptor agonist, and Mounjaro is tirzepatide, a dual GIP and GLP-1 receptor agonist — which is why they behave differently in trials even though they look identical in the pen.

The short version. Both are once-weekly injections that help people eat less by acting on the gut-brain signalling governing appetite and fullness. Semaglutide engages one incretin receptor; tirzepatide engages two. In the only large head-to-head trial in adults with obesity, tirzepatide produced greater average weight reduction, while semaglutide produced a result extraordinary by any pre-2020 standard and carries the longer cardiovascular outcome record. Both are excellent tools. The right one is the one you can tolerate, access consistently and stay on.

Four Brand Names, Two Molecules: The Map Everyone Wants

Semaglutide is sold as Ozempic and as Wegovy. Same molecule, two brands. Ozempic carries the type 2 diabetes label; Wegovy carries the chronic weight management label and goes to a higher maintenance dose (2.4 mg weekly).

Tirzepatide is sold as Mounjaro and as Zepbound. Same molecule, two brands. Mounjaro carries the type 2 diabetes label; Zepbound carries the chronic weight management label. The dose ladder runs to 15 mg weekly on both.

So "Mounjaro vs Ozempic" is really "tirzepatide vs semaglutide," and it is the same comparison as "Zepbound vs Wegovy." If one person says they lost weight on Wegovy and another says Ozempic, they took the same drug at different doses under different labels. Our overview of GLP-1 therapy in Ann Arbor covers the class as a whole, and we have separate pages on semaglutide and tirzepatide.

How Each One Works

Semaglutide: one receptor, deeply studied

GLP-1 is a hormone your small intestine releases when you eat. It prompts glucose-dependent insulin release, slows gastric emptying so food stays with you longer, and signals satiety in the hypothalamus and brainstem. Semaglutide is a long-acting analogue of it, engineered so one weekly injection maintains steady exposure. The effect patients describe is that the constant background negotiation about food quiets down — portions shrink without willpower doing the work.

Tirzepatide: two receptors, a different lever

Tirzepatide activates the GLP-1 receptor and also the receptor for glucose-dependent insulinotropic polypeptide (GIP), a second incretin hormone with its own effects on insulin secretion and on how fat tissue handles nutrients. Adding that signal appears to change the magnitude of what the drug can do rather than duplicating the first — which is why a head-to-head trial was worth running.

The Head-to-Head Trial: SURMOUNT-5

SURMOUNT-5 is the trial people are actually asking about. It was a phase 3b, open-label, controlled trial in 751 adults with obesity but without type 2 diabetes, randomised to the maximum tolerated dose of tirzepatide (10 or 15 mg) or of semaglutide (1.7 or 2.4 mg), once weekly for 72 weeks.

At week 72, the least-squares mean weight change was −20.2% (95% CI, −21.4 to −19.1) with tirzepatide and −13.7% (95% CI, −14.9 to −12.6) with semaglutide (P<0.001). Waist circumference fell 18.4 cm with tirzepatide and 13.0 cm with semaglutide (P<0.001). Participants on tirzepatide were more likely to reach reductions of at least 10%, 15%, 20% and 25%. The most common adverse events in both groups were gastrointestinal, mostly mild to moderate, and occurred primarily during dose escalation (Aronne et al., N Engl J Med, 2025, DOI).

Read that in both directions. Tirzepatide won the primary endpoint, clearly. And semaglutide delivered a 13.7% average reduction with a 13 cm waist change — a result no lifestyle programme reliably produces. This is not a good drug versus a bad drug, but two very good drugs with different average magnitudes.

Quality of life moved with both. In a prespecified SURMOUNT-5 analysis, SF-36v2 physical component scores improved from baseline in both arms (p < 0.001), with greater improvement in the General Health domain on tirzepatide (5.45 vs 4.20; p = 0.003), and those who lost the most weight gained most in physical functioning and bodily pain whichever drug they took (Shukla et al., Diabetes Obes Metab, 2025, DOI).

Glycaemic Effect: Where the Comparison Started

Before the obesity head-to-head there was SURPASS-2, an open-label 40-week phase 3 trial in 1,879 adults with type 2 diabetes, randomised to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg. Mean HbA1c fell 2.01, 2.24 and 2.30 percentage points on the three tirzepatide doses and 1.86 points on semaglutide; tirzepatide was non-inferior and superior at every dose. Weight reductions were also greater with tirzepatide (treatment differences of 1.9, 3.6 and 5.5 kg). Gastrointestinal events were the most common on both: nausea 17–22% versus 18%, diarrhoea 13–16% versus 12%, vomiting 6–10% versus 8% (Frías et al., N Engl J Med, 2021, DOI).

Two things stand out: the glycaemic gap is real but narrow, and the tolerability profiles in that trial were close to overlapping.

What Each Achieved Against Placebo

Semaglutide, STEP 1. 1,961 adults with overweight or obesity and without diabetes, randomised 2:1 to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% versus −2.4%; 86.4% reached at least 5%, 69.1% at least 10% and 50.5% at least 15%. Cardiometabolic risk factors and self-reported physical functioning improved (Wilding et al., N Engl J Med, 2021, DOI).

Tirzepatide, SURMOUNT-1. 2,539 adults without diabetes, randomised to tirzepatide 5, 10 or 15 mg or placebo for 72 weeks. Mean weight change was −15.0%, −19.5% and −20.9% versus −3.1%. Half of the 10 mg group and 57% of the 15 mg group lost at least 20% of body weight (Jastreboff et al., N Engl J Med, 2022, DOI).

With diabetes in the picture, SURMOUNT-2 studied tirzepatide 10 and 15 mg against placebo in 938 adults over 72 weeks: −12.8% and −14.7% versus −3.2% (Garvey et al., Lancet, 2023, DOI). Weight reduction runs lower alongside diabetes on either molecule — normal, and worth expecting.

Timelines: What to Expect, and When

Both drugs start low and climb, titrated over roughly 16 to 20 weeks in monthly steps so the gut adapts. That escalation is not a delay to be endured; it is how the drug becomes tolerable. Appetite change is often noticeable within the first few weeks, but the headline percentages above are 15- to 18-month figures, not 12-week figures.

Speed varies enormously. A post hoc SURMOUNT-5 analysis classified those reaching at least 15% reduction by week 24 as rapid responders: 32.3% overall, 44% on tirzepatide and 21% on semaglutide. They reached higher week-72 thresholds and reported somewhat more gastrointestinal and hepatobiliary adverse events, but completed treatment at similar rates to everyone else (Aronne et al., Am J Med, 2026, DOI). Being a slower responder is common and is not a sign of failure.

Side Effects and Tolerability

These two molecules have broadly similar side-effect profiles, and the profile is dominated by the gut. Across SURMOUNT-5, SURPASS-2, STEP 1 and SURMOUNT-1, the most common adverse events on both were gastrointestinal — nausea, diarrhoea, vomiting, constipation — mostly mild to moderate, concentrated during dose escalation, and diminishing with time on a stable dose (Aronne et al., 2025, DOI; Frías et al., 2021, DOI).

Discontinuation rates give a sense of scale. In STEP 1, 4.5% of the semaglutide group stopped because of gastrointestinal events versus 0.8% on placebo (Wilding et al., 2021, DOI); in SURMOUNT-1, adverse events caused discontinuation in 4.3–7.1% across tirzepatide doses versus 2.6% on placebo (Jastreboff et al., 2022, DOI). The great majority completed treatment.

In practice, tolerability is largely a dosing-strategy question rather than a fixed property of the molecule. Slowing an escalation step, holding a dose longer, and adjusting meal size, timing, hydration and fibre are the levers we use. Nobody should be white-knuckling through nausea in silence; that is a call to the clinic.

Beyond Weight: The Outcome Evidence

Weight and HbA1c are surrogates. What patients want is a longer, healthier life, and here the two molecules have different depths of evidence.

Semaglutide has the longer outcome record. In SELECT, 17,604 adults aged 45 or over with pre-existing cardiovascular disease and a BMI of 27 or greater, without diabetes, received semaglutide 2.4 mg or placebo. Over a mean 39.8 months, the composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 6.5% versus 8.0% (hazard ratio 0.80; 95% CI 0.72 to 0.90; P<0.001) (Lincoff et al., N Engl J Med, 2023, DOI). Earlier, SUSTAIN-6 randomised 3,297 people with type 2 diabetes at high cardiovascular risk over 104 weeks: 6.6% versus 8.9% (hazard ratio 0.74). It also reported lower rates of new or worsening nephropathy and a higher rate of retinopathy complications on semaglutide, which is one reason eye history is part of our intake (Marso et al., N Engl J Med, 2016, DOI).

Tirzepatide's cardiovascular trial is newer. SURPASS-CVOT randomised 13,299 patients with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide up to 15 mg or dulaglutide 1.5 mg — an active comparator already shown to reduce cardiovascular events, a demanding benchmark. The primary composite occurred in 12.2% versus 13.1%, meeting non-inferiority (Nicholls et al., N Engl J Med, 2025, DOI).

Where the evidence is genuinely thinner: there is no completed cardiovascular outcome trial of tirzepatide in people with obesity but without diabetes comparable to SELECT, and none has compared cardiovascular outcomes between the two molecules directly. We will not speculate about how such a trial would read.

What Happens If You Stop

This is the part that matters most and gets discussed least, and both molecules answer it the same way.

In STEP 4, adults who had lost a mean 10.6% during a 20-week semaglutide run-in were randomised to continue or switch to placebo. Over 48 weeks the continued group lost a further 7.9% while the placebo group regained 6.9% (Rubino et al., JAMA, 2021, DOI). In SURMOUNT-4, adults who had lost a mean 20.9% during a 36-week tirzepatide lead-in were similarly randomised; over 52 weeks the continued group lost a further 5.5% while the placebo group regained 14.0%, and 89.5% of those continuing maintained at least 80% of their lead-in loss versus 16.6% on placebo (Aronne et al., JAMA, 2024, DOI).

Obesity behaves like a chronic condition, and these medications behave like treatments for one. Planning for the long arc — nutrition, resistance training to protect lean mass, sleep and stress — is not an optional add-on to the injection. It is what makes the injection worth taking.

Cost, Supply and Access

Coverage differs by plan, by which brand is on your formulary, and by whether you are being treated for diabetes or for weight, so two people on the same molecule can pay very different amounts. Manufacturer savings programmes exist for both and change periodically. Supply across this class has fluctuated since demand outran manufacturing capacity, and availability of a given dose in a given week is a real constraint we plan around.

The useful framing: the best drug for you is the one you can obtain reliably every week for a year. A slightly lower average reduction you stay on beats a higher one you abandon at month four.

How the Choice Is Actually Made at Arbour

We will not pick one from a web page. Here is what the decision genuinely turns on.

What we are treating. Weight alone, weight with type 2 diabetes, or weight with cardiovascular disease are different starting points, and the evidence maps onto them differently. Someone with established cardiovascular disease and no diabetes sits squarely in the population SELECT studied (Lincoff et al., 2023, DOI).

Your target and timeline. If the goal requires a large magnitude of change, SURMOUNT-5 is directly relevant (Aronne et al., 2025, DOI). If a moderate, steady reduction is the goal, either molecule reaches it.

Your gut, your history and your other medications. Prior gastrointestinal problems, gallbladder and pancreatitis history, thyroid and family history, retinopathy, current diabetes medications and pregnancy plans all shape what is appropriate. That is an in-person assessment, and it is the part a comparison article cannot do for you.

What you can access and sustain. Coverage, supply, how a titration schedule fits your life, and what surrounds the injection — protein, resistance training, sleep and follow-up cadence. Our medical weight loss programme is built around that, and our weight loss shots page explains how the injections fit inside it.

Nothing on this page is a diagnosis or a recommendation for any individual.

Frequently Asked Questions

Is Mounjaro better than Ozempic for weight loss?

In the one large head-to-head trial in adults with obesity without diabetes, tirzepatide produced greater average weight reduction than semaglutide at 72 weeks: −20.2% versus −13.7%, with waist reductions of 18.4 cm versus 13.0 cm (Aronne et al., 2025, DOI). "Better for you" is a different question, and depends on tolerability, your medical history, coverage and supply.

Are Ozempic and Wegovy the same thing? What about Mounjaro and Zepbound?

Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide. Within each pair, one brand carries the type 2 diabetes label and the other carries the chronic weight management label, and the dose ranges differ. Four brands, two molecules.

Can I switch from Ozempic to Mounjaro, or the other way?

Switching is a common clinical decision and is made in person, because the dose ladders are not interchangeable and the restart point depends on where you are, how you tolerated the first, and why you are switching. Please do not improvise a conversion at home — call (734) 436-3357 and we will plan it properly.

Which one has fewer side effects?

Neither has a clearly gentler profile. In SURPASS-2 the rates were close: nausea 17–22% on tirzepatide versus 18% on semaglutide, diarrhoea 13–16% versus 12% (Frías et al., 2021, DOI). How an individual tolerates a given titration matters more than the molecule.

How long until I see results?

Appetite change is often noticed within the first few weeks, but the published weight figures are measured at 68 to 72 weeks. About a third of SURMOUNT-5 participants reached at least 15% reduction by week 24 — meaning about two thirds did not, and still did well by week 72 (Aronne et al., 2026, DOI).

What happens if I stop?

Weight tends to return. In the withdrawal trials, participants switched to placebo regained 6.9% over 48 weeks after semaglutide (Rubino et al., 2021, DOI) and 14.0% over 52 weeks after tirzepatide, while those who continued kept losing (Aronne et al., 2024, DOI). We plan for this from the first visit.

Mounjaro and Ozempic Consultations in Ann Arbor

We assess in person before recommending a molecule, because the trial averages above describe populations and you are an individual. We offer semaglutide and tirzepatide within a structured medical weight loss programme, alongside our broader GLP-1 care.

Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC is a triple board certified nurse practitioner. We are at 2217 Packard St #15, in the Eastover Professional Center, Ann Arbor, MI 48104, open Thursday through Monday, 10am to 7pm, closed Tuesday and Wednesday. Parking is free and directly outside — no meters and no parking structure. Suite 15 is down a flight of stairs; if stairs are difficult for you, please call (734) 436-3357 before your visit so we can make arrangements.

Call (734) 436-3357 or book your first visit. The first visit is $35, applied toward your treatment plan. Cash pay, HSA and FSA accepted.

Clinical information on this page is drawn from articles retrieved from PubMed and is provided for education. It is not medical advice, not a diagnosis, and not a promise of any individual result.